Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

0.41 EUR-1.09 %4.9, 17.29
5,778 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-1.09 %
-14.78 %
-20.33 %
-27.04 %
-79.48 %
-81.48 %
-89.29 %
-91.19 %
-87.74 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
93.32M EUR
Turnover
549.03K EUR
P/E (adj.) (26e)
-4.56
EV/EBIT (adj.) (26e)
-3.69
P/B (26e)
21.34
EV/S (26e)
20,833.45
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
26.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 27.08.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Pentwater has never owned such a large share of Faron that it would have been required to flag it under the First North Finland rules. They received 6 million shares, which is below First North Finland’s 5% flagging threshold. They could have sold those 6 million shares in March-...
16 hours ago
by OsakasOssi
9
The information can be found in the offering prospectus. I would actually encourage everyone considering participating in an offering to read through that booklet for every company before making a decision, even though it is often hundreds of pages long. Here are the relevant excerpts...
14 hours ago
6
[quote="Tuul1puku, post:4886, topic:66933"]\nPentwater has converted its share issue shares into a swap\n\n[/quote]\n\nThis would practically mean selling. They received 6 million shares from the share issue, but in the June flaggings (notification of major shareholdings) they did...
20 hours ago
by OsakasOssi
6
The acquisition price for the guarantors is probably just under 40 cents, when taking the guarantee fee into account.
18 hours ago
by Tuul1puku
5
ValkoisenPeura makes a very good point. It would seem somewhat like Pentwater received about 8.59 million shares from the share issue, assuming the shares left for the underwriters were distributed pro rata. Perhaps some clarity on this will emerge at some point. I’m still a bit ...
13 hours ago
by OsakasOssi
3
I had no idea about this. Where can such information be found? I have been under the impression that Pentwater was an anchor investor, but they did not participate in subscribing for the unsubscribed shares. So, according to my understanding, they were not involved in guaranteeing...
14 hours ago
by OsakasOssi
2
Do you mean by that that they received 6 million shares in the share issue? Pentwater was both an anchor investor in the share issue with a 3 million euro pot and an underwriting guarantor (merkintätakaaja) with a 3 million euro pot. Based on the anchor investment, they received ...
14 hours ago
2
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release04.09.2026, 12.00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Press release28.08.2026, 10.35

Redeye: Faron Pharmaceuticals (H1 Review): Setting up for an eventful period of clinical development

Faron Pharmaceuticals
Press release28.08.2026, 08.34

DNB Carnegie Access: Faron Pharmaceuticals: BEXERA trial on track to start in Q4 – H1 review

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Faron H1'26: New trials set to get underway
Research27.08.2026, 10.20 by
Antti Siltanen

Faron H1'26: New trials set to get underway

Several new trials will begin in the coming months.

Faron Pharmaceuticals
Press release27.08.2026, 08.00

Faron Announces First Patient Enrolled in BEXAR Investigator-Initiated Trial

Faron Pharmaceuticals
Faron Pharmaceuticals, H1'26
Webcast26.08.2026, 14.00

Faron Pharmaceuticals, H1'26

Faron Pharmaceuticals
Regulatory press release26.08.2026, 08.00

Faron Pharmaceuticals Ltd: Half-year financial results 1 January – 30 June 2026

Faron Pharmaceuticals
Faron H1'26 preview: BEXERA trial is being initiated
Analyst Comment25.08.2026, 09.37 by
Antti Siltanen

Faron H1'26 preview: BEXERA trial is being initiated

The company's key value driver, the BEXERA trial, will start in H2.

Faron Pharmaceuticals
Regulatory press release19.08.2026, 08.00

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Faron Pharmaceuticals
Regulatory press release05.08.2026, 13.00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release04.08.2026, 15.00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release03.08.2026, 14.00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Faron Pharmaceuticals
Faron reports first OS results from frontline MDS patients
Analyst Comment28.07.2026, 08.33 by
Antti Siltanen

Faron reports first OS results from frontline MDS patients

Median overall survival has not been reached in 2/3 of patient groups after 14.9 months of follow-up.

Faron Pharmaceuticals
Regulatory press release27.07.2026, 08.00

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Faron Pharmaceuticals
Regulatory press release24.07.2026, 08.00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron updated the status of investigator-initiated bexmarilimab studies
Analyst Comment14.07.2026, 08.16 by
Atte Riikola

Faron updated the status of investigator-initiated bexmarilimab studies

The bexmarilimab cohort in the FINPROVE trial was discontinued, but the company's own blood cancer trials are moving forward.

Faron Pharmaceuticals
Press release13.07.2026, 08.00

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Faron Pharmaceuticals
Regulatory press release01.07.2026, 12.00

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release22.06.2026, 15.00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release17.06.2026, 15.30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals